<p>NWF Advisory Services Inc. 在最近向證券交易委員會提交的文件中表示，在第二季度其在禮來公司的股份增加了 103.1%。該基金在季度內購買了額外的 1,002 股後，持有該公司 1,974 股股票。截至其最近的 SEC 文件，NWF Advisory Services Inc. 在禮來公司的持股價值為 1,539,000 美元。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<ul>
<li>黃金交叉提醒：3 只具有重大上漲潛力的股票</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也增加或減少了在 LLY 的持股。Lazard Freres Gestion S.A.S. 在第二季度將其在禮來公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S. 現在擁有 77,295 股該公司的股票，價值 60,253,000 美元，此前在上個季度購買了 41,222 股。Precedent Wealth Partners LLC 在第二季度將其在禮來公司的股份增加了 15.3%。Precedent Wealth Partners LLC 現在擁有 294 股該公司的股票，價值 229,000 美元，此前在上個季度購買了 39 股。Capital Advisors Inc. OK 在第二季度將其在禮來公司的股份增加了 6.8%。Capital Advisors Inc. OK 現在擁有 6,747 股該公司的股票，價值 5,260,000 美元，此前在上個季度購買了 429 股。Family CFO Inc 在第二季度收購了禮來公司的新股份，價值 54,000 美元。最後，Duquesne Family Office LLC 在第一季度將其在禮來公司的股份增加了 52.5%。Duquesne Family Office LLC 現在擁有 94,830 股該公司的股票，價值 78,321,000 美元，此前在上個季度購買了 32,640 股。對沖基金和其他機構投資者持有該公司 82.53% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位分析師最近對 LLY 股票發佈了報告。Leerink Partners 將禮來公司的評級從 “市場表現” 上調至 “跑贏大盤”，並將其目標價格從 886.00 美元上調至 1,104.00 美元，報告發佈於 11 月 10 日星期一。Erste Group Bank 在 10 月 14 日星期二將禮來公司的評級從 “持有” 上調至 “買入”。Guggenheim 在 12 月 3 日星期三重申了 “買入” 評級，並將禮來公司的目標價格設定為 1,163.00 美元。Berenberg Bank 在 12 月 2 日星期二將禮來公司的目標價格從 830.00 美元上調至 950.00 美元，並給予該公司 “持有” 評級。最後，Wall Street Zen 在 11 月 1 日星期六將禮來公司的評級從 “買入” 上調至 “強力買入”。三位投資分析師對該股票給予了強力買入評級，十六位分析師給予了買入評級，六位分析師給予了持有評級。根據 MarketBeat 的數據，禮來公司目前的平均評級為 “適度買入”，平均目標價格為 1,121.90 美元。</p>
<ul>
<li>2026 年將主導的三大投資主題</li>
</ul>
<p><strong>查看我們最新的禮來公司股票報告</strong></p>
<h2>禮來公司的價格表現</h2>
<p>禮來公司的股票在週一開盤價為 1,027.68 美元。禮來公司的 1 年最低價為 623.78 美元，1 年最高價為 1,111.99 美元。該公司的債務與股本比率為 1.71，速動比率為 1.24，流動比率為 1.55。該公司的 50 日移動平均價格為 939.47 美元，200 日移動平均價格為 820.35 美元。該公司的市值為 9715.5 億美元，市盈率為 50.28，PEG 比率為 1.14，貝塔值為 0.37。</p>
<ul>
<li>5 個醫療保健領域值得關注的公司，因行業輪動正在全面展開</li>
</ul>
<p>禮來公司（NYSE:LLY - 獲取免費報告）最近在 10 月 30 日星期四公佈了季度財報。該公司報告每股收益（EPS）為 7.02 美元，超出市場共識預期的 6.42 美元，超出幅度為 0.60 美元。該公司在本季度的收入為 176 億美元，而分析師預期為 160.9 億美元。禮來公司的淨利潤率為 30.99%，股本回報率為 109.52%。該公司的季度收入較去年同期增長了 53.9%。在去年同期，該公司每股收益為 1.18 美元。禮來公司已將其 2025 財年的指引設定為 23.000-23.700 EPS。賣方分析師預測禮來公司今年將發佈 23.48 美元的每股收益。</p>
<h2>禮來公司增加股息</h2>
<p>該公司最近還披露了季度股息，將於 3 月 10 日星期二支付。2 月 13 日星期五的股東將獲得 1.73 美元的股息。這是禮來公司之前季度股息 1.50 美元的積極變化。除息日期為 2 月 13 日星期五。這相當於年化股息 6.92 美元，股息收益率為 0.7%。禮來公司的股息支付比率（DPR）為 29.35%。</p>
<h2>禮來公司公司簡介</h2>
<p>（免費報告）</p>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過禮來公司</li>
<li>投資於高市盈率成長股</li>
<li>3 只被低估的機器人股票，準備迎來鉅額收益</li>
<li>比較和交易高市盈率股票</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了遊戲</li>
<li>股票市場行業：它們是什麼，有多少個？</li>
<li>3 只金融股票在 10 年期國債收益率上升時值得購買</li>
</ul>
<p><strong>想知道其他對 LLY 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Eli Lilly and Company (NYSE:LLY - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Eli Lilly and Company 嗎？</h2>
<p>在考慮 Eli Lilly and Company 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Eli Lilly and Company 並不在名單上。</p>
<p>雖然 Eli Lilly and Company 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>NWF Advisory Services Inc. 在第二季度將其在禮來的股份增加了 103.1%，持有 1,974 股，價值 1,539,000 美元。其他投資者也調整了他們的持倉。分析師上調了禮來的股票評級，平均目標價為 1,121.90 美元。禮來報告第三季度每股收益為 7.02 美元，超出預期，營收同比增長 53.9%</p>

<p>NWF Advisory Services Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 103.1% during the second quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund owned 1,974 shares of the company's stock after buying an additional 1,002 shares during the quarter. NWF Advisory Services Inc.'s holdings in Eli Lilly and Company were worth $1,539,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>NWF Advisory Services Inc. 在最近向證券交易委員會提交的文件中表示，在第二季度其在禮來公司的股份增加了 103.1%。該基金在季度內購買了額外的 1,002 股後，持有該公司 1,974 股股票。截至其最近的 SEC 文件，NWF Advisory Services Inc. 在禮來公司的持股價值為 1,539,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黃金交叉提醒：3 只具有重大上漲潛力的股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Lazard Freres Gestion S.A.S. grew its position in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC lifted its stake in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK lifted its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $54,000. Finally, Duquesne Family Office LLC increased its position in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after buying an additional 32,640 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也增加或減少了在 LLY 的持股。Lazard Freres Gestion S.A.S. 在第二季度將其在禮來公司的股份增加了 114.3%。Lazard Freres Gestion S.A.S. 現在擁有 77,295 股該公司的股票，價值 60,253,000 美元，此前在上個季度購買了 41,222 股。Precedent Wealth Partners LLC 在第二季度將其在禮來公司的股份增加了 15.3%。Precedent Wealth Partners LLC 現在擁有 294 股該公司的股票，價值 229,000 美元，此前在上個季度購買了 39 股。Capital Advisors Inc. OK 在第二季度將其在禮來公司的股份增加了 6.8%。Capital Advisors Inc. OK 現在擁有 6,747 股該公司的股票，價值 5,260,000 美元，此前在上個季度購買了 429 股。Family CFO Inc 在第二季度收購了禮來公司的新股份，價值 54,000 美元。最後，Duquesne Family Office LLC 在第一季度將其在禮來公司的股份增加了 52.5%。Duquesne Family Office LLC 現在擁有 94,830 股該公司的股票，價值 78,321,000 美元，此前在上個季度購買了 32,640 股。對沖基金和其他機構投資者持有該公司 82.53% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several analysts have recently issued reports on LLY shares. Leerink Partners upgraded Eli Lilly and Company from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their price objective for the company from $886.00 to $1,104.00 in a research report on Monday, November 10th. Erste Group Bank upgraded shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, October 14th. Guggenheim reiterated a &#34;buy&#34; rating and set a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $1,121.90.</p>
<div class="lb-trans"><p>幾位分析師最近對 LLY 股票發佈了報告。Leerink Partners 將禮來公司的評級從 “市場表現” 上調至 “跑贏大盤”，並將其目標價格從 886.00 美元上調至 1,104.00 美元，報告發佈於 11 月 10 日星期一。Erste Group Bank 在 10 月 14 日星期二將禮來公司的評級從 “持有” 上調至 “買入”。Guggenheim 在 12 月 3 日星期三重申了 “買入” 評級，並將禮來公司的目標價格設定為 1,163.00 美元。Berenberg Bank 在 12 月 2 日星期二將禮來公司的目標價格從 830.00 美元上調至 950.00 美元，並給予該公司 “持有” 評級。最後，Wall Street Zen 在 11 月 1 日星期六將禮來公司的評級從 “買入” 上調至 “強力買入”。三位投資分析師對該股票給予了強力買入評級，十六位分析師給予了買入評級，六位分析師給予了持有評級。根據 MarketBeat 的數據，禮來公司目前的平均評級為 “適度買入”，平均目標價格為 1,121.90 美元。</p>
</div><ul>
<li>The Top 3 Investment Themes That Will Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年將主導的三大投資主題</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的禮來公司股票報告</strong></p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>禮來公司的價格表現</h2>
</div><p>Eli Lilly and Company stock opened at $1,027.68 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm has a 50 day moving average price of $939.47 and a 200 day moving average price of $820.35. The company has a market cap of $971.55 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.14 and a beta of 0.37.</p>
<div class="lb-trans"><p>禮來公司的股票在週一開盤價為 1,027.68 美元。禮來公司的 1 年最低價為 623.78 美元，1 年最高價為 1,111.99 美元。該公司的債務與股本比率為 1.71，速動比率為 1.24，流動比率為 1.55。該公司的 50 日移動平均價格為 939.47 美元，200 日移動平均價格為 820.35 美元。該公司的市值為 9715.5 億美元，市盈率為 50.28，PEG 比率為 1.14，貝塔值為 0.37。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 個醫療保健領域值得關注的公司，因行業輪動正在全面展開</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business's quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>禮來公司（NYSE:LLY - 獲取免費報告）最近在 10 月 30 日星期四公佈了季度財報。該公司報告每股收益（EPS）為 7.02 美元，超出市場共識預期的 6.42 美元，超出幅度為 0.60 美元。該公司在本季度的收入為 176 億美元，而分析師預期為 160.9 億美元。禮來公司的淨利潤率為 30.99%，股本回報率為 109.52%。該公司的季度收入較去年同期增長了 53.9%。在去年同期，該公司每股收益為 1.18 美元。禮來公司已將其 2025 財年的指引設定為 23.000-23.700 EPS。賣方分析師預測禮來公司今年將發佈 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>禮來公司增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 3 月 10 日星期二支付。2 月 13 日星期五的股東將獲得 1.73 美元的股息。這是禮來公司之前季度股息 1.50 美元的積極變化。除息日期為 2 月 13 日星期五。這相當於年化股息 6.92 美元，股息收益率為 0.7%。禮來公司的股息支付比率（DPR）為 29.35%。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>禮來公司公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Investing in the High PE Growth Stocks</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過禮來公司</li>
<li>投資於高市盈率成長股</li>
<li>3 只被低估的機器人股票，準備迎來鉅額收益</li>
<li>比較和交易高市盈率股票</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了遊戲</li>
<li>股票市場行業：它們是什麼，有多少個？</li>
<li>3 只金融股票在 10 年期國債收益率上升時值得購買</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 LLY 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Eli Lilly and Company (NYSE:LLY - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Eli Lilly and Company 嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eli Lilly and Company 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Eli Lilly and Company 並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eli Lilly and Company 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NWF Advisory Services Inc. 購買了禮來公司 $LLY 的股票